Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
Compounded GLP-1 RAs may be associated with a higher odds of AEs, safety concerns, and product quality issues compared to non-compounded products. These findings underscore the importance of cautious prescribing, rigorous quality standards, and enhanced patient monitoring.
Authors
- Rowan G. Casey (ORCID: https://orcid.org/0000-0001-6910-0219)
- Brian J. Piper (ORCID: https://orcid.org/0000-0002-2295-445X)
- Ewa K. Sulicz
- Kenneth L. McCall (ORCID: https://orcid.org/0000-0003-2061-108X)
- Keri A. Mastro Dwyer
- S.K. Tso
- Tasnia N Samana
- Emma R Yalanzhi
Institutions
- Binghamton University (US)
- Center for Innovation (US)
- Geisinger Commonwealth School of Medicine (US)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1080/14740338.2025.2499670
- Citations
- 13
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 17.00